Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited on October 11, 2022. The transaction is in cash consideration and Marksans has agreed to retain the site employees with existing terms of employment. The transaction is subject to the usual closing conditions. The transaction is expected to be finalized by April 1, 2023. Torreya acted as the exclusive financial advisor to Marksans Pharma Limited on their acquisition.

Marksans Pharma Limited (BSE:524404) completed the acquisition of Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited on April 19, 2023. Nitin Lath, Hetal Vora of Stifel Financial Corp. acted as financial advisor to Marksans Pharma Limited.